A Randomized, Open Label, Single/Multiple Dose, Crossover Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With DWC202001 and DWC202002 in Healthy Male Adults
Latest Information Update: 09 Apr 2022
At a glance
- Drugs DWC 202001 (Primary) ; DWC 202002 (Primary) ; Enavogliflozin (Primary)
- Indications Metabolic disorders; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Daewoong Pharmaceutical
- 14 Apr 2020 New trial record